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There is growing evidence that dysbiosis of the gut microbiota is associated with the pathogenesis of both
intestinal and extra-intestinal disorders. Intestinal disorders include inflammatory bowel disease, irritable
bowel syndrome (IBS), and coeliac disease, while extra-intestinal disorders include allergy, asthma, metabolic
syndrome, cardiovascular disease, and obesity.
In many of these conditions, the mechanisms leading to disease development involves the pivotal mutualistic
relationship between the colonic microbiota, their metabolic products, and the host immune system. The
establishment of a ‘healthy’ relationship early in life appears to be critical to maintaining intestinal homeostasis.
Whilst we do not yet have a clear understanding of what constitutes a ‘healthy’ colonic microbiota, a picture is
emerging from many recent studies identifying particular bacterial species associated with a healthy microbiota. In
particular, the bacterial species residing within the mucus layer of the colon, either through direct contact with host
cells, or through indirect communication viabacterial metabolites, may influence whether host cellular homeostasis
is maintained or whether inflammatory mechanisms are triggered. In addition to inflammation, there is some
evidence that perturbations in the gut microbiota is involved with the development of colorectal cancer. In this case,
dysbiosis may not be the most important factor, rather the products of interaction between diet and the
microbiome. High-protein diets are thought to result in the production of carcinogenic metabolites from the
colonic microbiota that may result in the induction of neoplasia in the colonic epithelium.
Ever more sensitive metabolomics methodologies reveal a suite of small molecules produced in the microbiome
which mimic or act as neurosignallers or neurotransmitters. Coupled with evidence that probiotic interventions
may alter psychological endpoints in both humans and in rodent models, these data suggest that CNS-related
co-morbidities frequently associated with GI disease may originate in the intestine as a result of microbial dysbiosis.
This review outlines the current evidence showing the extent to which the gut microbiota contributes to
the development of disease. Based on evidence to date, we can assess the potential to positively modulate the
composition of the colonic microbiota and ameliorate disease activity through bacterial intervention.
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T
he human intestinal microbiota is made up of
trillions of microorganisms most of which are of
bacterial and viral origin that are considered to
be non-pathogenic (1, 2). The microbiota functions in
tandem with the host’s defences and the immune system
to protect against pathogen colonisation and invasion. It
also performs an essential metabolic function, acting as a
source of essential nutrients and vitamins and aiding in
the extraction of energy and nutrients, such as short-chain
fatty acids (SCFA) and amino acids, from food. Ulti-
mately, the host depends on its intestinal microbiota for a
number of vital functions and thus the intestinal micro-
biota may contribute to health. It is, however, difficult to
describe the precise impact of the intestinal microbiota on
human health and the involvement in human disease.
Alterations in the microbiota can result from exposure
to various environmental factors, including diet, toxins,
drugs, and pathogens. Of these, enteric pathogens have the
greatest potential to cause microbial dysbiosis as seen
in experimental animal models, where foodborne viral
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pathogens can trigger both local and systemic inflamma-
tion altering the composition of the microbiota and
barrier function, as a mechanism for developing auto-
immunity, as shown in type 1 diabetes and T-cell mediated
destruction of insulin-producing pancreatic b-cells (35).
Documenting dysbiosis has traditionally relied on classi-
cal microbiological techniques and the ability to culture
pure isolates for identification and classification, which is
necessarily limited to ‘culturable’ microorganisms. The
advent of high-throughput DNA based pyrosequencing
technology to classify bacteria and archaea according to
individual 16S rRNA sequences directly from human
samples (usually faecal in origin) with no need for cultur-
ing now provides a rapid and detailed means of profiling
complex communities of microorganisms. Since the first
application of this technology, it has been shown that the
composition of the intestinal microbiota varies substan-
tially amongst individuals (6). This can in part be ex-
plained by genetic differences amongst hosts with positive
relationships between similarity in dominant faecal micro-
bial communities and genetic relatedness of the host being
observed (7). At the phylum level, Bacteroidetes and
Firmicutes dominate with Proteobacteria, Actinobacteria,
Fusobacteria, Spriochaetes, Verrucomicrobia, and Len-
tisphaerae also present (8, 9). Using metagenomic analysis
to investigate the functional capability of the intestinal
microbiota genome (microbiome), it has been shown that
almost 40% of the microbial genes present in each indi-
vidual are shared with at least half the general population
providing evidence for the existence of a functional core,
or core microbiome (10). The main approach to studying
changes in composition of the intestinal microbiota in
relation to disease has relied primarily on the phylogenetic
characterisation of the microbiota of diseased individuals
in comparison with apparently healthy individuals. How-
ever, since there are substantial inter-individual and intra-
individual variations in addition to age-related changes in
the composition of the intestinal microbiota, it is difficult
to establish precise relations between human health and
the presence and relative abundance of specific microbial
communities. It may be possible in the future to use spe-
cific changes in compositional diversity, or even functional
diversity, as biomarkers for health or specific diseases. It is
important to note, however, that it is questionable whether
changes in phylogenetic composition are a cause or con-
sequence of a given disease.
Arguably the strongest evidence of the direct involve-
ment in or requirement for the intestinal microbiota in
disease pathogenesis comes from studies using germ-free
mouse models of human autoimmune disease in which
the requirement for exposure to and colonisation by
environmental microorganisms on disease initiation and
progression can be determined (Table 1). In most but not
all of the disease models, the severity and/or incidence of
disease is reduced under germ-free conditions consistent
with the microbiota being a ‘trigger’ for disease progres-
sion. However, attempts to identify the members of the
‘pathogenic’ microbiota (pathobionts) that can reproduce
the effect of the microbiota as a whole have to date failed.
It is perhaps not surprising that intestinal dysbiosis is
most often associated with GI-related diseases in which
alterations in the interaction of the host (immune system)
with lumen-derived stimuli and antigens initiate and/or
perpetuate uncontrolled inflammation in the intestinal
mucosa, and in some cases beyond.
Metabolomic impact of the interaction between
diet and the microbiome on human health
Food components that escape digestion in the small in-
testine, as well as endogenous compounds such as diges-
tive enzymes and shed epithelial cells and associated
mucus, enter the colon and become available for fermen-
tation by the colonic microbiota. Bacterial conversion of
these compounds results in a wide variety of metabolites
that are in close contact with host’s cells. In this way,
these metabolites can affect the metabolic phenotype of
the host and influence the risk of disease (11).
Undigested carbohydrates and proteins constitute the
major substrates at the disposal of the microbiota.
Fermentation of these substrates results in the production
of a range of metabolites including SCFA, branched
chain fatty acids, ammonia, amines, phenolic compounds,
and gases, including hydrogen, methane, and hydrogen
sulphide. In addition, the intestinal microbiota is involved
in the production of vitamins, the activation or inactiva-
tion of bioactive food components such as isoflavanoids
Table 1. The intestinal microbiota and autoimmunity
Disease Microbiota status Disease impact
Inflammatory bowel disease Germ free, antibiotics or probiotics No disease or reduced severity
Spontaneous arthritis Germ free No disease
Autoimmune arthritis Germ free No disease
Autoimmune encephalomyelitis Germ-free Weak severity
Systemic lupus erythematosus Germ free No change
Type 1 diabetes Germ free No disease
Spontaneous ankylosing enteropathy Germ free or probiotics No disease
Simon Carding et al.
2
(page number not for citation purpose)
Citation: Microbial Ecology in Health & Disease 2015, 26: 26191 - http://dx.doi.org/10.3402/mehd.v26.26191
and plant lignans, the conversion of prodrugs to their
bioactive forms, and the transformation of bile acids and
xenobiotics (12, 13).
Mechanistic effect of metabolites on host health
The SCFA acetate, propionate, and butyrate are the major
anions in the colon and are mainly produced by bacterial
fermentation of undigested carbohydrates. Up to 95% of
produced SCFA are readily absorbed by the colonocytes
for use as energy substrates. As colonocytes derive up to
6070% of their energy needs from SCFA oxidation (14),
SCFA provide about 10% of the daily caloric requirements
in humans (15). The fraction that is not consumed by the
colonocytes is transported across the basolateral mem-
brane to the liver via the portal blood stream. Besides their
local role as energy substrates within the colon, SCFA act
as signalling molecules involved in systemic lipid metabo-
lism and glucose/insulin regulation (16). These effects
are, at least partly, mediated through interaction with
two specific G-protein-coupled receptors  GPR41 and
GPR43 (later renamed to FFAR3 and FFAR2, respec-
tively) (17) that are widely distributed throughout the
human body, including the small intestine and colon (18).
Within the cells, SCFA can act as inhibitors of histone
deacetylases to induce hyperacetylation of histones which
affects gene expression and results in anti-inflammatory
properties, induction of growth arrest, and apoptosis (19).
However, an integrated understanding of the impact of
SCFA on host metabolism requires more quantitative data
on fluxes of SCFA in different body compartments. Due to
its inaccessibility, little information is available on in vivo
production rates of SCFA and kinetics of absorption in the
large intestine.
Plant polyphenols have been associated with health
benefits including anti-inflammatory, antiestrogenic, car-
dioprotective, chemoprotective, and neuroprotective ef-
fects (10). However, the mechanistic evidence in vivo is not
yet fully understood. The majority of plant polyphenols
require metabolic transformation (including deglycation
and hydrolysis) to render them biologically active. Within
the colon, they are broken down by the microbiota to a
variety of small phenolic compounds of which the physio-
logical relevance is not well known (20). In addition, recent
studies indicate a selective modulation of the microbiota
composition after polyphenol consumption (21). For
instance, consumption of red wine polyphenols signifi-
cantly increases Enterococcus, Prevotella, Bacteroides,
Bifidobacterium, Bacteroides uniformis, Eggerthella lenta,
and Blautia coccoides-Eubacterium rectale numbers in
healthy humans (22). Therefore, the health benefits asso-
ciated with polyphenols should not only be attributed to
their bioactive metabolites but also to the modulation of
the intestinal microbiota.
Other products of bacterial metabolism have been
associated with diseases affecting the liver, cardiovascular
system and the kidneys.
In recent years, the gutliver axis and the impact of the
intestinal microbiota on liver function has gained increas-
ing attention. The liver is extensively exposed to metabo-
lites produced at intracolonic fermentation as it receives
70% of its blood supply from the intestine through the
portal vein (23). In the early 1980s, a possible causative
role of the microbiota in the development of non-alcoholic
fatty liver disease (NAFLD) was suggested. In patients
that underwent intestinal bypass surgery, hepatic steatosis
developed in parallel with bacterial overgrowth. Interest-
ingly, the steatosis regressed after treatment with the
antibiotic, metronidazole (24). One of the mechanisms
relating the microbiota to NAFLD is bacterial metabolism
of choline. In mice susceptible to NAFLD and fed a high-
fat diet, choline was increasingly metabolised to methyla-
mines resulting in high urinary excretion of dimethylamine
(DMA) and trimethylamine (TMA) and correspondingly
low levels of serum phosphatidylcholine (25).
Due to conversion of choline into methylamines by the
microbiota, the bioavailability of choline is reduced, re-
sulting in the inability to synthesise phosphatidylcholine
with subsequent accumulation of triglycerides in the liver.
This mimics choline-deficient diets which have been con-
sistently associated with hepatic steatosis (26).
The bacterial metabolite TMA is consequently absorbed
by the intestinal mucosa and transported to the liver via the
portal vein where it is oxidised to trimethylamine N-oxide
(TMAO) by the flavin mono-oxygenase (FMO) enzyme
complex. In a metabolomics study profiling the plasma of
patients undergoing elective cardiac evaluation, TMAO
was identified and confirmed as a predictor of cardiovas-
cular disease (CVD). Subsequent mice experiments con-
firmed the obligate role of the intestinal microbiota in the
formation of TMAO and indicated the pro-atherogenic
nature of TMAO by augmentation of cholesterol loaded
macrophages and foam cell formation (27). Similarly,
metabolism by the intestinal microbiota of dietary L-
carnitine, a TMA abundant in red meat, also produced
TMAO and accelerated atherosclerosis in mice (28).
Dysbiosis in disease
Dysbiosis and GI-tract-related disorders
Inflammatory bowel disease
Crohn’s disease (CD) and ulcerative colitis (UC) are the
most prevalent forms of inflammatory bowel disease
(IBD), characterised by chronic relapsing inflammation
affecting the intestinal mucosa. Although the aetiology of
both diseases is unknown, there is increasing evidence that
intestinal microbial dysbiosis has a role in the pathogenesis
of IBD (29). Overall, patients exhibit a decrease in micro-
bial population and functional diversity and stability of
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their intestinal microbiota with decreases in specific
Firmicutes and a concomitant increase in Bacteroidetes
and facultative anaerobes such as Enterobacteriaceae (30).
Significant differences in the microbiota of CD versus
UC patients have also been noted (31, 32). In CD, the
predominant dysbiosis has been described to be associated
with five bacterial species amongst which alterations in the
abundance of Faecalibacterium prausnitzii is associated
with the prolongation of disease remission (32, 33), with
this bacterium having a therapeutic effect in experimental
models of colitis (34). Conversely, adherent-invasive E. coli
and Mycobacterium paratuberculosis have been implicated
in CD pathogenesis although a causal relationship is yet to
be demonstrated (35, 36). Indeed, up to now, it is still
unclear whether intestinal microbial dysbiosis is a direct
cause for the inflammation in IBD, or merely the result of a
disturbed environment in the GI-tract. One study that has
sought to determine the status of the microbiota in early-
diagnosis CD cases is that of Gevers et al. (Cell Host
Microbe 2014) (37). This study analysed the microbiota of
a large cohort of newly diagnosed paediatric CD patients
and found clear differences in bacterial populations be-
tween CD and healthy control patients. CD patients had
increased abundance of Enterobacteriaceae, Pasteurel-
laceae, Veillonellaceae, and Fusobacteriaceae, and de-
creased abundance in Erysipelotrichales, Bacteroidales,
and Clostridiales compared to healthy control patients.
Interestingly, these differences were only revealed when
analysing mucosal samples (rather than faecal samples),
indicating that the bacteria resident in the mucosal layer
may be more significant for disease aetiology.
Dysbiosis and other GI-tract disorders
In addition to IBD, metabolic disorders, obesity, and type
2 diabetes (T2D), the intestinal microbiota has also been
implicated in several other (chronic) GI-related diseases
and disorders, such as irritable bowel syndrome (IBS),
coeliac disease, and colorectal cancer (CRC). In IBS,
changes in microbiota composition have been described in
the different subtypes of disease compared to healthy
individuals (38, 39) although the changes are not uniform
(40). Coeliac disease and CRC have also been associated
with alterations in microbiota composition with increased
diversity and richness observed compared to control sub-
jects (41, 42). In all of these diseases, however, no con-
sistent pattern of microbiota changes has yet been
observed. In the case of coeliac disease, however, a recent
study has shed light on the interaction between host
genetics and microbiota composition in relation to disease
development. Expression of the leukocyte antigen DQ2 is
a strong risk factor for the development of coeliac disease.
Children with this haplotype have an altered microbiota
composition (compared to non-HLA DQ2 individuals)
prior to clinically apparent disease (43). Coeliac disease
results from CD4 T-cell reactivity to dietary gliadin, with
some bacterial species being able to digest gliadin and
perhaps therefore reduce the immunopathogenicity of
ingested gliadin.
Dysbiosis in systemic disease
Metabolic disorders
An increase in the relative abundance of Firmicutes and a
reduction in the level of Bacteroidetes have been observed
in both obese mice (44) and humans (45) although these
findings have not been replicated in all studies (4652). Of
note, intestinal dysbiosis is not currently used as a factor in
diagnosing or predicting onset of a metabolic disease such
as obesity or T2D. More subtle changes in the composi-
tion of the intestinal microbiota have been described in
obese individuals with a reduced compositional microbial
diversity compared with lean individuals (7). Additional
evidence implicating the intestinal microbiota in obesity
originates from obese (ob/ob) mice that lack expression of
the gene encoding leptin, the product of which promotes
satiety. In support of the involvement of the microbiota
in the development of obesity in these mice, antibiotic
treatment conferred changes in the gut microbiota, redu-
cing the incidence of metabolic endotoxemia, inflamma-
tion, and several obesity-linked parameters (53). In human
populations, it is evident that a high-fat diet and over-
consumption of food are responsible for the greater
prevalence of obesity and T2D in the West, thus conspir-
ing to alter host metabolism and immune homeostasis via
diet-induced changes in the intestinal microbiota. Indeed,
the role of the microbiota in metabolism, and notably its
ability to harvest energy from food, highlight a significant
environmental factor impacting the risk of metabolic
disease. A direct link between intestinal microbiota com-
position and body weight comes from studies using germ-
free mice to show that the absence of intestinal microbes
protects against diet-induced obesity, and that the intest-
inal microbiota is involved in the regulation of fat storage
(5456). These and similar studies have led to the proposal
that obese individuals are more efficient in converting
food into useable energy and in storing this energy in fat
than lean individuals, which is related to, and may be a
consequence of, the functionality of the intestinal micro-
biota. Major insights into differences between various
physiological states of the host, such as in obese versus
lean individuals, should therefore be obtained by studying
the functional microbial diversity in addition to phyloge-
netic diversity. Indeed, an altered representation of
bacterial genes and metabolic pathways, including those
involved in nutrient harvest, has been found to be related
to obesity (7). Also, the amount of SCFA produced by
the intestinal microbiota, rather than the changes in the
composition of the microbiota, is important in the
development of obesity (51). Perhaps unsurprisingly, shifts
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in microbiota phyla have also been described in T2D (57),
with metagenomics-based studies identifying discriminant
metagenomic markers that may differ between different
ethnicities of patients (58, 59). The question remains
whether dysbiosis of the intestinal microbiota is a direct
cause for any metabolism-related disorder, or whether
changes in the intestinal microbial communities in affected
and obese individuals are an adaptation to a change in the
host’s diet. Two observations relevant to answering this
question are one, that the transfer of microbiota from lean
donors into individuals with metabolic syndrome can
increase insulin sensitivity and overall amelioration of
symptoms of metabolic disease (60) and two, dietary
changes in humans leads to rapid and reversible changes in
the relative abundance of dominant members of the
intestinal microbiota (61).
The potential interaction between host physiology,
behaviour, the microbiome, and diet is evidenced in both
animal and human studies showing rapid changes in
microbiota composition after Roux-en-Y gastric bypass
surgery (RYGB) (52, 62) although the impact on metabo-
lite levels has been less explored. Nevertheless, in a non-
obese rat model, RYGB surgery resulted in profound
metabolic perturbations (63). Besides lower concentrations
of oligosaccharides and higher concentrations of SCFA,
increased levels of colonic protein fermentation metabo-
lites were found in faecal samples obtained after surgery.
These results might point at an incomplete digestion of
proteins in the small intestine as a result of the bypass
leading to an increased supply of protein to the colon with
increased protein fermentation. Interestingly, faecal water
samples obtained 2 and 8 weeks after the operation, dis-
played significantly more cytotoxicity compared to the
samples obtained from sham-operated animals (64). It
needs to be investigated whether the observed association
between increased levels of amino acid fermentation me-
tabolites and increased cytotoxicity also involves a causal
relationship. In healthy, normal weight subjects, increased
protein fermentation after a high-protein diet was not
associated with increased faecal water cytotoxicity (65).
Also, between the large intestine and the kidney, a
bi-directional functional relationship exists. Uremia in-
fluences the colonic microbial metabolism whereas micro-
bial-related metabolites are involved in the progression of
the kidney disease (66). p-Cresyl sulphate and indoxyl
sulphate have been most extensively studied and are
considered as prototypes of the so-called uremic toxins.
They are derived from bacterial fermentation of the
aromatic amino acids tyrosine and tryptophan, respec-
tively, followed by sulphation in the colonic mucosa or the
liver. Within the plasma, they are highly protein-bound
and accumulate when kidney function fails. The free,
unbound levels of these solutes increase more than their
total plasma levels due to competition for binding sites on
plasma proteins (67). In patients with chronic kidney
disease, both p-cresyl sulphate and indoxyl sulphate levels
have been linked to overall mortality, CVD and progres-
sion of the kidney disease (68).
Dysbiosis and CNS-related disorders
Intestinal microbial dysbiosis has also been observed in
extra-intestinal diseases and in particular those that may
impact on the ‘gutbrainaxis’ to affect the CNS and
behaviour and cognitive function.
Several studies have focused on the possibility that the
intestinal microbiota may influence cognitive function and
behaviour by direct reprogramming of the hypothalamus
pituitaryadrenal (HPA) axis, a common pathway acti-
vated in response to infection and perturbed by psycho-
logical stressors. It is known that enteric infections can
cause anxiety, depression, and cognitive dysfunction;
germ-free mice that have no intestinal microbiota display
alterations in stress-responsivity, central neurochemistry,
and behaviour indicative of a reduction in anxiety in
comparison to conventionalised mice (43). For example, in
germ-free mice, increased anxiety-like behaviour has been
associated with changes in the production of neurotrophic
factors and hormones and expression of their receptors
(69). In pathogen-infected mice (7073), Campylobacter
jejuni (a common cause of gastroenteritis) can induce
anxiety-like behaviour in mice and brainstem activation
(the nucleus tractus solitarius and lateral parabrachial
nucleus). Commensal bacteria may affect brain changes
through GABA, which can directly influence receptors
both immune and neural within the ENS and CNS (74,
75). GABA is the main CNS inhibitory neurotransmitter
and is involved in regulating physiological and psycholo-
gical processes. Alterations in central GABA receptor
expression are implicated in the pathogenesis of anxiety
and depression (76).
Early colonisation of the intestinal tract by microbes is
known to be important for the post-natal development of
the enteric nervous system (77). Accordingly, intestinal
microbiota may have implications on the development
and function of the CNS (78, 79).
Evidence of a possible causal role of the intestinal
microbiota in the development of autism spectrum
disorder (ASD) comes from a maternal immune activation
(MIA) mouse model in which pregnant animals after
being administered the viral mimetic, ploy(I:C), display
increased intestinal permeability and develop stereotypi-
cal abnormalities in behaviour, social ability, and commu-
nication that resemble ASD (80). MIA offspring display
intestinal dysbiosis and an altered serum metabolomic
profile, characterised by excessive levels of microbiota-
derived 4-ethylphenylsulphate (4EPS), compared to con-
trol offspring, with intestinal barrier function being
restored and ASD-like symptoms being alleviated after
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administering probiotic bacteria. Of particular note, exo-
genously administered 4EPS, which is structurally related
to the toxic sulphated form of p-cresol, resulted in an
anxiety-like behaviour in naı¨ve mice, suggesting that
autism, and maybe other behavioural conditions, involve
the GI-tract eventually impacting on the immune, meta-
bolic, and nervous systems.
With the emerging preclinical data and indications in
developmental disorders, it is perhaps no coincidence that
GI-tract disorders including IBD and IBS are common
co-morbidities in debilitating stress-related disorders,
including depression and anxiety (81, 82). Recent re-
search suggested that intestinal permeability and bacter-
ial translocation may drive immuno-inflammatory and
oxidative and nitrosative stress (IO&NS) pathways in
depression and thus play a role in its pathophysiology.
Chronic depression in humans was shown to be accom-
panied by increased immune response (serum IgM and
IgA responses) directed against lipopolysaccharide (LPS)
products of gram negative gut enterobacteria, that is,
Hafnia alvei, Pseudomonas aeruginosa, Morganella mor-
ganii, Pseudomonas putida, Citrobacter koseri, and
Klebsiella pneumonia (83). Attempts have been made to
examine the potential CNS and behavioural impact of
bacteriotherapy in germ-free and pathogen-infected ro-
dents. Germ-free mice exhibit hyper-responsive HPA axis
activity following stress as compared to specific-pathogen
free mice (78) and this hyper-response of the HPA axis
was reversed by Bifidobacterium infantis (84). B. infantis
increased plasma tryptophan levels, decreased serotonin
metabolite concentrations in the frontal cortex and
dopamine metabolite concentrations in the amygdaloid
cortex (85), both of which are implicated in depression
(86, 87). In humans, the efficacy of probiotics for mood
regulation was suggested in a trial of Lactobacillus casei
that showed subjects with the lowest scores in the
depressed/elated dimension at baseline had significant
improvement in mood scores after taking the probiotic
compared to the placebo group (88). The combination of
L. helveticus and B. longum reduced anxiety and had
beneficial psychological effects with decreased serum
cortisol in healthy human volunteers (89).
Functional brain activity measured by functional mag-
netic resonance (fMRI) showed that a probiotic formula-
tion reduced brain intrinsic connectivity and response to
emotive stimuli and changes in midbrain connectivity (90).
However, it should be noted that several studies have
failed to observe an effect of probiotic supplementation
on anxiety measures in clinical populations, including
IBS (91, 92), schizophrenia (93), and rheumatoid arthritis
(94). This may be explained in part by the spectrum of
doses, species (and combinations thereof), and timings
used in probiotic interventions and the lack of a standard
trial design.
Future approaches: restoration of the intestinal
microbiota through bacteriotherapy
There is huge potential for manipulating the microbiota
to sustain, improve, or restore the microbiota in at risk or
diseased individuals.
An important pre-requisite for bacteria-based therapy
(bacteriotherapy) is defining what constitutes a ‘healthy’
microbiota during and throughout life, which may be
defined differently at the population and individual level.
More research is needed to examine species and strain
diversity in the GI-tract, the diversity of microbial genes
(microbiome), and what their functionality is in the GI-
tract throughout human development  from the cradle
to the grave! Therapeutically, probiotic-based approaches
have been used with some success for centuries (95, 96), as
have the more drastic and cruder approach of wholesale
microbiota replacement strategies based upon faecal
transplantation (97). The application of these procedures
is discussed in more detail in a separate review in this
supplement  Manipulating the gut microbiota to main-
tain health and treat disease. The development and use of
these and other more refined approaches using chemi-
cally defined bacterial products in the clinic will rely on
understanding their molecular mechanisms of action and
the particular host features requiring personalisation of
approach in order to enable bacterial/probiotic therapies
to yield their full potential in the treatment and manage-
ment of human health.
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